Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
- 25 July 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (30), 11252-11257
- https://doi.org/10.1073/pnas.0604812103
Abstract
α-Galactosylceramide (α-GalCer) is the prototype compound for studying the presentation of glycolipids on CD1d molecules to natural killer T (NKT) lymphocytes. A single i.v. dose of glycolipid triggers a cascade of events involving the production of several cytokines over the course of a day, a short-lived activation of NKT and natural killer (NK) cells, and a more prolonged adaptive T cell immune response if certain antigens are given together with α-GalCer. We find that a recently described analogue, α-C-galactosylceramide (α-C-GalCer), more potently induces these innate and adaptive immune responses in mice. α-C-GalCer acts as a more effective trigger for IL-12 and IFN-γ production, although it minimally elicits IL-4 and TNF-α release into the serum. Also, α-C-GalCer better mobilizes NKT and natural killer cells to resist B16 melanoma. To help understand these effects, we find that α-C-GalCer binds more stably to dendritic cells than α-GalCer and that dendritic cells loaded with α-C-GalCer induce larger and more long lasting NKT cell responses in vivo. When glycolipid is targeted to dendritic cells in spleen together with antigens in dying cells, such as irradiated tumor cells, α-C-GalCer is active as an adjuvant for T cell-mediated immunity at lower doses, just 20 ng per mouse, where it is also able to up-regulate the required CD40L costimulatory molecule on NKT cells. Therefore, α-C-GalCer represents a glycolipid that binds more stably to dendritic cells and acts as a more effective link between innate and adaptive immunity in vivo.Keywords
This publication has 29 references indexed in Scilit:
- Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cellsThe Journal of Experimental Medicine, 2005
- Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patientsThe Journal of Experimental Medicine, 2005
- Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infectionsNature, 2005
- Recognition of bacterial glycosphingolipids by natural killer T cellsNature, 2005
- Minute numbers of contaminant CD8+ T cells or CD11b+CD11c+ NK cells are the source of IFN-γ in IL-12/IL-18-stimulated mouse macrophage populationsBlood, 2005
- Lysosomal Glycosphingolipid Recognition by NKT CellsScience, 2004
- The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune ResponseAnnual Review of Immunology, 2003
- The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In VivoThe Journal of Experimental Medicine, 2002
- Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria VaccinesThe Journal of Experimental Medicine, 2002
- The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies.The Journal of Experimental Medicine, 1990